[1]

Income from continuing operations before provision/(benefit) for taxes on income.

[2]

Certain production facilities are shared. Depreciation is allocated based on estimates of physical production.

[3]

Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above. Earnings in the third quarter and the first nine months of 2026 reflect a charge of $650 million recorded in Acquired in-process research and development expenses related to an in-licensing and collaboration agreement with Innovent (see Note 2E). Earnings in the third quarter and the first nine months of 2025 reflected a charge of $1.35 billion recorded in Acquired in-process research and development expenses related to an in-licensing agreement with 3SBio.

[4]

Earnings in the third quarter and the first nine months of 2026 include, among other things, restructuring charges/(credits), inventory write-offs, implementation costs and additional depreciation—asset restructuring of $893 million and $1.6 billion for the third quarter and the first nine months of 2026, respectively (primarily recorded in Restructuring charges and certain acquisition-related costs). Earnings in the first nine months of 2026 also include, among other things, (i) certain asset impairments of $4.3 billion and (ii) charges for certain legal matters of $1.0 billion, partially offset by (iii) a net gain of $1.870 billion from the sale of our previous investment in ViiV (all recorded in Other (income)/deductions––net). Earnings in the first nine months of 2025 included, among other items, (i) restructuring charges/(credits), inventory write-offs, implementation costs and additional depreciation—asset restructuring of $1.0 billion (primarily recorded in Restructuring charges and certain acquisition-related costs), (ii) charges for certain legal matters of $755 million and (iii) certain asset impairments of $577 million (items (ii) and (iii) recorded in Other (income)/deductions––net). See Notes 3 and 4.

[5]

In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation

[6]

Biopharma’s earnings include dividend income from our previous investment in ViiV of $58 million in the third quarter of 2026 and $72 million in the third quarter of 2025, and $239 million in the first nine months of 2026 and $184 million in the first nine months of 2025 recorded in Other (income)/deductions––net. Biopharma’s earnings in the third quarter and the first nine months of 2025 also reflected credits to Cost of Sales representing favorable revisions of our estimate of accrued royalties.